Cholesteryl ester transfer protein: Pharmacological inhibition for the modulation of plasma cholesterol levels and promising target for the prevention of atherosclerosis

Current Topics in Medicinal Chemistry

Volumn 5, Issue 3, 2005, Pages 257-264

  Ruggeri, Roger B ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; ATORVASTATIN; BENZENE DERIVATIVE; BENZYL DERIVATIVE; CHOLESTEROL; CHOLESTEROL ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DIBENZYLAMINE; DIPHENYL ETHER DERIVATIVE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYL GROUP; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LACTONE DERIVATIVE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHANOL DERIVATIVE; NAPHTHOL DERIVATIVE; NICOTINIC ACID; PENICILLIN DERIVATIVE; PYRIDINE DERIVATIVE; QUINOLINE DERIVATIVE; TORCETRAPIB; TRIACYLGLYCEROL; U 106305; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG POTENTIATION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; FLUSHING; GASTROINTESTINAL DISEASE; HUMAN; NONHUMAN; PROTEIN DEFICIENCY; REVIEW; RISK REDUCTION; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; TRIACYLGLYCEROL BLOOD LEVEL;

ANTILIPEMIC AGENTS; ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; CARRIER PROTEINS; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; DRUG DELIVERY SYSTEMS; GLYCOPROTEINS; HUMANS; LIPOPROTEINS; RANDOMIZED CONTROLLED TRIALS;

EID: 18144425549     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026053544506     Document Type: Review

References (56)

1. Schaefer, E. J.; Brousseau, M. E. Benefits of Reducing Low-Density Lipoprotein Cholesterol Concentrations to <100 mg/dL. Prev. Cardiol. 2000, 3, 136-139.
2. Scandinavian Simvastatin Survival Study Group. Randomised Trial of Cholesterol Lowering in 4,444 Patients With Heart Disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344, 1383-1389.
3. Shepherd, J.; Cobbe, S. M.; Ford, I.; Isles, C. G.; Lorimer, A. R.; Macfarlane, P. W.; McKillop, J. H.; Packard, C. J. Prevention of Coronary Heart Disease With Pravastatin in Men with Hypercholesterolemia. N. Engl. J. Med. 1995, 333, 1301-7.
4. Sacks, F. M.; Pfeffer, M. A.; Moye, L. A.; Rouleau, J. L.; Rutherford, J. D.; Cole, T. G.; Brown, L.; Warnica, J. W.; Arnold, J. M.; Wun, C. C.; Davis, B. R.; Braunwald, E. The Effect of Pravastatin on Coronary Events After Myocardial Infarction in Patients With Average Cholesterol Levels. N. Engl. J. Med. 1996, 335, 1001-1009.
5. Downs, J. R.; Clearfield, M.; Weis, S.; Whitney, E.; Shapiro, D. R.; Beere, P. A.; Langendorfer, A.; Stein, E. A.; Kruyer, W.; Gotto, A. M. Jr. Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/Texcaps. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998, 279, 1615-22.
6. Barter P.; Kastelein J.; Nunn A.; Hobbs R. High Density Lipoproteins (HDLs) and Atherosclerosis; The Unanswered Questions. Atherosclerosis 2003, 168, 195-211.
7. Gordon, D. J.; Probstfield, J. L.; Garrison, R. J.; Neaton, J. D.; Castelli, W. P.; Knoke, J. D.; Jacobs, D. R. Jr.; Bangdiwala, S.; Tyroler, H. A. High-Density Lipoprotein Cholesterol and Cardiovascular Disease. Four Prospective American Studies. Circulation 1989, 79, 8-15.
8. Assmann, G.; Gotto, A.M. HDL Cholesterol and Protective Factors in Atherosclerosis. Circulation 2004, 109, (23, Suppl.), III/8-III/14.
9. Barter, P. CETP and Atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2000, 20, 2029-2031.
10. Goldbourt U.; Yaari S.; Medalie J. H. Isolated Low HDL Cholesterol as a Risk Factor for Coronary Heart Disease. Arterioscler. Thromb. Vasc. Biol. 1997, 17, 107-113.
11. Genest J. J.; McNamara J. R.; Salem D. N.; Schaefer E. J. Prevalence of Risk Factors in Men With Premature Coronary Heart Disease. Am. J. Cardiol. 1991, 67, 1185-1189.
12. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J A M A 2001, 285, 2486-2497.
13. Ellison, R. C.; Zhang, Y.; Qureshi, M. M.; Knox, S.; Arnett, D. K.; Province, M. Investigators of the NHLBI Family Heart Study. Lifestyle Determinants of High-density. Lipoprotein Cholesterol: the National Heart, Lung, and Blood Institute Family Heart Study. Am. Heart J. 2004, 147, 529-35.
14. Bays, H.; Stein, E. A. Pharmacotherapy For Dyslipidaemia - Current Therapies and Future Agents. Expert Opin. Pharmacother. 2003, 4, 1901-1938.
15. Tall, A. R. Plasma Cholesteryl Ester Transfer Protein. J. Lipid. Res. 1993, 34, 1255-1274.
16. Bruce, C.; Beamer, L. J.; Tall, A. R. The Implications of the Structure of the Bactericidal/Permeability-Increasing Protein on the Lipid-Transfer Function of the Cholesteryl Ester Transfer Protein. Curr. Opin. Struct. Biol. 1998, 8, 426-434.
17. Barter, P. J.; Brewer, H. B.; Chapman, M. J.; Hennekens, C. H.; Rader, D. J.; Tall, A. R. Cholesteryl Ester Transfer Protein - A Novel Target for Raising HDL and Inhibiting Atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2003, 23, 160-167.
18. Kuller, L.; Arnold, A.; Tracy, R.; Otvos, J.; Burke, G.; Psaty, B.; Siscovick, D.; Freedman, D. S.; Kronmal, R. Nuclear Magnetic Resonance Spectroscopy of Lipoproteins and Risk of Coronary Heart Disease in the Cardiovascular Health Study. Arterioscler. Thromb. Vasc. Biol. 2002, 22, 1175-1180.
19. Freedman, D. S.; Otvos, J. D.; Jeyarajah, E. J.; Shalaurova, I.; Cupples, L. A.; Parise, H.; D'Agostino, R. B.; Wilson, P. W. F.; Schaefer, E. J. Sex and Age Differences in Lipoprotein Subclasses Measured by Nuclear Magnetic Resonance Spectroscopy: The Framingham Study. Clin. Chem. 2004, 50, 1189-1200.
20. Boekholdt, S. M.; Kuivenhoven, J.-A.; Hovingh, G. K.; Jukema, J. W.; Kastelein, J. J. P.; van Tol, A. CETP Gene Variation: Relation to Lipid Parameters and Cardiovascular Risk. Curr. Opin. Lipidol. 2004, 15, 393-398.
21. Brown, M. L.; lnazu, A.; Hesler, C. B. Molecular Basis of Lipid Transfer Protein Deficiency in a Family With Increased High-Density Lipoproteins. Nature 1989, 342, 448-451.
22. Inazu, A.; Brown, M. L.; Hesler, C. B.; Agellon, L. B.; Koizumi, J.; Takata, K.; Maruhama, Y.; Mabuchi, H.; Tall, A. R. Increased High-Density Lipoprotein Levels Caused by a Common Cholesteryl-Ester Transfer Protein Gene Mutation. N. Engl. J. Med. 1990, 323, 1234-8.
23. Le Goff, W.; Guerin, M.; Chapman, M. J. Pharmacological Modulation of Cholesteryl Ester Transfer Protein, a New Therapeutic Target in Atherogenic Dyslipidemia. Pharmacol. Ther. 2004, 101, 17-38.
24. Hirano, K.-I.; Yamashita, S.; Matsuzawa, Y. Pros and Cons of Inhibiting Cholesteryl Ester Transfer Protein. Curr. Opin. Lipidol. 2000, 11, 589-596.
25. Zhong, S.; Sharp, D. S., Grove, J. S.; Bruce, C.; Yano, K.; Curb, J. D.; Tall, A. R. Increased Coronary Heart Disease in Japanese-American Men With Mutation in the Cholesteryl Ester Transfer Protein Gene Despite Increased HDL Levels. J. Clin. Invest. 1996, 97, 2917-23.
26. Curb, J. D.; Abbott, R. D.; Rodriguez, B. L.; Masaki, K.; Chen, R.; Sharp, D. S.; Tall, A. R. A Prospective Study of HDL-C and Cholesteryl Ester Transfer Protein Gene Mutations and the Risk of Coronary Heart Disease in the Elderly. J. Lipid Res. 2004, 45, 948-953.
27. Boekholdt, S. M.; Thompson, J. F. Natural Genetic Variation as a Tool in Understanding the Role Of CETP in Lipid Levels And Disease. J. Lipid Res. 2003, 44, 1080-1093.
28. Ordovas, J. M.; Cupples, L. A.; Corella, D.; Otvos, J. D.; Osgood, D.; Martinez, A.; Lahoz, C.; Coltell, O.; Wilson, P. W. F.; Schaefer, E. J. Association of Cholesteryl Ester Transfer Protein-Taqib Polymorphism With Variations in Lipoprotein Subclasses and Coronary Heart Disease Risk: The Framingham Study. Arterioscler. Thromb. Vasc. Biol. 2000, 20, 1323-1329.
29. Barzilai, N.; Atzmon, G.; Schechter, C.; Schaefer, E. J.; Cupples, A. L.; Lipton, R. . Unique lipoprotein Phenotype and Genotype Associated with Exceptional Longevity. JAMA 2003, 290, 2030-40.
30. Marotti, K. R.; Castle, C. K.; Boyle, T. P.; Lin, A. H.; Murray, R. W.; Melchior, G. W. Severe Atherosclerosis in Transgenic Mice Expressing Simian Cholesteryl Ester Transfer Protein. Nature 1993, 364, 73-5.
31. Bruce, C.; Chouinard, R. A. Jr.; Tall, A. R. Plasma Lipid Transfer Proteins, High-Density Lipoproteins, and Reverse Cholesterol Transport. Annu. Rev. Nutr. 1998, 18, 297-330.
32. Sugano M.; Makino N.; Sawada S.; Otsuka S.; Watanabe M.; Okamoto H.; Kamada M.; Mizushima A. Effect of Antisense Oligonucleotides Against Cholesteryl Ester Transfer Protein on the Development of Atherosclerosis in Cholesterol-Fed Rabbits. J. Biol. Chem. 1998, 273, 5033-6.
33. Rittershaus, C. W.; Miller, D. P.; Thomas, L. J.; Picard, M. D.; Honan, C. M.; Emmett, C. D.; Pettey, C. L.; Adari, H.; Hammond, R. A.; Beattie, D. T.; Callow, A. D.; Marsh, H. C.; Ryan, U. S. Vaccine-Induced Antibodies Inhibit CETP Activity in vivo and Reduce Aortic Lesions in a Rabbit Model of Atherosclerosis. Arterioseler. Thromb. Vasc. Biol. 2000, 20, 2106-2112.
34. Brewer, H. B. Jr. High-Density Lipoproteins: A New Potential Therapeutic Target for the Prevention of Cardiovascular Disease. Arterioscler. Thromb. Vasc. Biol. 2004, 24, 387-91.
35. Sikorski, J. A.; Connolly, K. T. The Discovery of New Cholesteryl Ester Transfer Protein Inhibitors. Curr. Opin. In Drug Discovery and Development 2001, 4, 602-13.
36. Wang, X.; Driscoll, D. M.; Morton, R. E. Molecular Cloning and Expression of Lipid Transfer Inhibitor Protein Reveals Its Identity With Apolipoprotein F. J. Biol. Chem. 1999, 274, 1814-1820.
37. Gautier, T.; Masson, D.; de Barros, J.; Athias, A.; Gambert, P. Aunis, D.; Metz-Boutigue, M. H.; Lagrost, L. Human Apolipoprotein C-1 Accounts For the Ability of Plasma High Density Lipoproteins to Inhibit the Cholesteryl Ester Transfer Protein Activity. J. Biol. Chem. 2000, 275, 37504-37509.
38. Kuo, M. S.; Zielinski, R. J.; Cialdelia, J. I.; Marschke, C. K.; Dupuis, M. J.; Li, G. P.; Kloosterman, D. A.; Spilman, C. H.; Marshall, V. P. Discovery, Isolation, Structure Elucidation, and Biosynthesis of U-106305, a Cholesteryl Ester Transfer Protein Inhibitor From UC 11136. J. Am. Chem. Soc. 1995, 117, 10629-34.
39. Bischoff, H.; Schmeck, C.; Schmidt, D.; Vakalopoulos, A.; Wirtz, G. Novel Use of Dioxocin-5-one Derivatives. WO 2004039364, October 31, 2002.
40. Chen, Z. X.; He, B. M.; Kawashima, A.; Akama, T.; Asami, Y.; Araki, H.; Hanada, K. Lipid Level Depressant Containing Penicillide Compound as Active Ingredient. WO 9412175, June 9, 1994.
41. Bischoff, H.; Hafner, F.-T.; Schmeck, C.; Telser, J.; Vakalopoulos, A.; Wirtz, G.; Bauser, M. Preparation of 7H-Dibenzo[b,g][1,5] dioxocin-5-one Derivatives and Their Use as Inhibitors of the Cholesteryl Ester Transfer Protein (CETP). WO 2004039453, October 31, 2002.
42. Paulsen, H.; Schmeck, C.; Brandes, A.; Schmidt, G.; Stoltefuss, J.; Wirtz, S. N.; Loegers, M.; Naab, P.; Bremm, K.-D.; Bischoff, H.; Schmidt, D.; Zaiss, S.; Antons, S. Fluorine-Substitution in Cholesteryl Ester Transfer Protein Inhibitors (CETP-Inhibitors) - Biology, Chemistry, SAR, and Properties. Chimia 2004, 58, 123-127.
43. Schmidt, G.; Angerbauer, R.; Brandes, A.; Loegers, M.; Muelier-Gliemann, M.; Bischoff, H.; Schmidt, D.; Wohlfeil, S. Preparation of 2-Arylpyridine-3-methanols and Analogs as Cholesteryl Ester Transfer Protein Inhibitors. Eur. Pat. Appl. 796846, March 7, 1997.
44. Schmidt, G.; Brandes, A.; Angerbauer, R.; Logers, M.; Muller-Gliemann, M.; Schmeck, C.; Bremm, K.-D.; Bischoff, H.; Schmidt, D.; Schuhmacher, J.; Giera, H.; Paulsen, H.; Naab, P.; Conrad, M.; Stoltefuss, J. Preparation of Tetrahydroquinolines and Analogs as Cholesteryl Ester Transfer Protein Inhibitors. German Patent DE 19627419, July 8, 1996.
45. Brandes, A.; Logers, M.; Stoltefuss, J.; Schmidt, G.; Bremm, K.- D.; Bischoff, H.; Schmidt, D.; Antons, S.; Paulsen, H.; Muller, S. N.; Naab, P.; Schmeck, C. Substituted Tetrahydronaphthalines as Cholesterol Ester Transfer Protein Inhibitors. WO 9914174, May 25, 1999.
46. Sikorski, J. A.; Durley, R. C.; Mischke, D. A.; Reinhard, E. J.; Fobian, Y. M.; Tollefson, M. B.; Wang, L.; Grapperhaus, M. L.; Hickory, B. S.; Massa, M. A.; Norton, M. B.; Vernier, W. F.; Promo, M. A.; Hamme, A. T.; Spangler, D. P.; Rueppel, M. L. (R)-Chiral Halogenated 1-Substituted Amino-(n+l)-alkanois Useful for Inhibiting Cholesteryl Ester Transfer Protein Activity. WO 2000018724, September 23, 1999.
47. Reinhard, E. J.; Wang, J. L.; Durley, R. C.; Fobian, Y. M.; Grapperhaus, M. L.; Hickory, B. S.; Massa, M. A.; Norton, M. B.; Promo, M. A.; Tollefson, M. B.; Vernier, W. F.; Connolly, D. T.; Witlierbee, B. J.; Melton, M. A.; Regina, Ka. J.; Smith, M. E.; Sikorski, J. A. Discovery of a Simple Picomolar Inhibitor of Cholesteryl Ester Transfer Protein. J. Med. Chem. 2003, 46, 2152-2168.
48. Kori, M.; Hamamura, K.; Fuse, H.; Yamamoto, T. Preparation of Aminoethanol Derivatives as Cholesteryl Ester Transfer Protein Inhibitors for Treatment of Hyperlipidemia. WO 2002059077, January, 25, 2002.
49. de Grooth, G. J.; Kuivenhoven, J. A.; Stalenhoef, A. F. H.; de Graaf, J.; Zwinderman, A, H.; Posma, J. L.; van Tol, A.; Kastelein, J. J. P. Efficacy and Safety of a Novel Cholesteryl Ester Transfer Protein Inhibitor, JTT-705, in Humans: A Randomized Phase II Dose-Response Study. Circulation 2002, 105, 2159-2165.
50. Okamoto, H.; Yonemori, F.; Wakitani, R.; Minowa, T.; Maeda, K.; Shinkal, H. A Cholesteryl Ester Transfer Protein Inhibitor Attenuates Atherosclerosis in Rabbits. Nature 2000, 406, 203-207.
51. Huang, Z.; Inazu, A.; Nohara, A.; Higashikata, T.; Mabuchi, H. Cholesteryl Ester Transfer Protein Inhibitor (JTT-705) and the Development of Atherosclerosis in Rabbits With Severe Hypercholesterolaemia. Clin. Sci. 2002, 103, 587-594.
52. Shinkai, H.; Maeda, K.; Yamasaki, T.; Okamoto, H.; Uchida, I. Bis2-(Acylamino)phenyl]Disulfides, 2-(Acylamino)benzenethiols, and S-2-(Acylamino)phenyl]Alkanethioates as Novel Inhibitors of Cholesteryl Ester Transfer Protein. J. Med. Chem. 2000, 43, 3566-3572
53. Maeda, K.; Nagamori, H.; Nakamura, H.; Shinkai, H.; Suzuki, Y.; Takahashi, D.; Taniguchi, T. Preparation of N-Phenyl or N-Heterocyclyldibenzylamine Compounds as Inhibitors of Cholesteryl Ester Transfer Protein (CETP) and Medicinal Use Thereof. WO 2004020393, August 29, 2003.
54. DeNinno, M. P.; Magnus-Aryitey, G. T.; Ruggeri, R. B.; Wester, R. T. Preparation of N-(1-Alkoxycarbonyl-1,2,3,4-tetrahydroquinolin-4-yl)carbamates as Cholesteryl Ester Transfer Protein Inhibitors. WO 200001716, March 30, 2000.
55. Clark, R. W.; Sutfin, T. A.; Ruggeri, R. B.; Willauer, A. T.; Sugarman, E. D.; Magnus-Aryitey, G.; Cosgrove, P. G.-, Sand, T. M.; Wester, R. T.; Williams, J. A.; Perlman, M. E.; Bamberger, M. J. Raising High-Density Lipoprotein in Humans Through Inhibition of Cholesteryl Ester Transfer Protein. Arterioscier. Thromb. Vasc. Biol. 2004, 24, 490-497.
56. Brousseau, M. E.; Schaefer, E. J.; Wolfe, M. L.; Bloedon, L. T.; Digenio, A. G.; Clark, R. W. Effects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol. N. Engl. J. Med. 2004, 350, 1505-15.